Tang Capital Management LLC boosted its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 750.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 850,268 shares of the biopharmaceutical company's stock after buying an additional 750,268 shares during the period. Tang Capital Management LLC owned 0.35% of Lexicon Pharmaceuticals worth $628,000 as of its most recent SEC filing.
A number of other hedge funds also recently added to or reduced their stakes in LXRX. Point72 Asset Management L.P. grew its stake in shares of Lexicon Pharmaceuticals by 630.7% in the fourth quarter. Point72 Asset Management L.P. now owns 8,988,421 shares of the biopharmaceutical company's stock worth $6,638,000 after purchasing an additional 7,758,371 shares in the last quarter. Schonfeld Strategic Advisors LLC grew its position in Lexicon Pharmaceuticals by 301.5% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 7,558,621 shares of the biopharmaceutical company's stock valued at $5,582,000 after buying an additional 5,676,021 shares in the last quarter. Nantahala Capital Management LLC raised its position in shares of Lexicon Pharmaceuticals by 186.6% during the 4th quarter. Nantahala Capital Management LLC now owns 6,604,150 shares of the biopharmaceutical company's stock worth $4,877,000 after buying an additional 4,300,000 shares in the last quarter. Boothbay Fund Management LLC acquired a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter worth approximately $355,000. Finally, Deutsche Bank AG boosted its holdings in shares of Lexicon Pharmaceuticals by 378.0% in the fourth quarter. Deutsche Bank AG now owns 315,659 shares of the biopharmaceutical company's stock valued at $234,000 after acquiring an additional 249,616 shares in the last quarter. 74.70% of the stock is currently owned by institutional investors.
Lexicon Pharmaceuticals Price Performance
Shares of NASDAQ:LXRX traded up $0.05 on Thursday, reaching $0.66. 3,901,302 shares of the company traded hands, compared to its average volume of 6,573,973. The stock has a market capitalization of $238.58 million, a PE ratio of -0.88 and a beta of 1.07. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. The company's 50 day moving average is $0.54 and its 200-day moving average is $0.69. Lexicon Pharmaceuticals, Inc. has a fifty-two week low of $0.28 and a fifty-two week high of $2.45.
Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last announced its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.03. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The company had revenue of $1.26 million for the quarter, compared to analyst estimates of $1.26 million. As a group, analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of research firms have weighed in on LXRX. Wall Street Zen assumed coverage on Lexicon Pharmaceuticals in a research report on Monday, April 21st. They issued a "sell" rating for the company. Piper Sandler cut their price objective on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating for the company in a report on Friday, March 7th. Leerink Partners reaffirmed a "market perform" rating and set a $1.00 target price (down from $2.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday, March 4th. Leerink Partnrs cut shares of Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Finally, Needham & Company LLC restated a "hold" rating on shares of Lexicon Pharmaceuticals in a research report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $3.67.
View Our Latest Report on LXRX
Lexicon Pharmaceuticals Profile
(
Free Report)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.
See Also
Before you consider Lexicon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.
While Lexicon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
